Macular degeneration is a disease that damages the macula, the center of the retina, and is one of the three major eye diseases along with glaucoma and diabetic retinopathy. The optic nerve and most of the photoreceptor cells are located here, and since this is where images of objects are formed, it is the most important area for vision. The main symptom of macular degeneration is the inability to clearly distinguish the shape of objects or the inability to distinguish colors and light and dark. It is also a serious eye disease that causes black spots in the center of the field of vision. However, it is difficult to distinguish it from the form of vision loss due to presbyopia, so early diagnosis is often missed. The most common treatment for macular degeneration is antibody injection therapy. This treatment requires regular injections once every 1-2 months. When receiving antibody injection therapy, the fear of having to inject directly into the eye and the cost of long-term repeated procedures are a great burden to patients. To overcome these problems, special sustained-release formulations using drug delivery systems are being developed. Since the release speed and release time of the drug can be controlled, the number of times the drug is administered can be drastically reduced. However, the implant (Ø 0.46×6.0mm), which is a sustained-release agent, is manufactured by mixing biodegradable resin (PLGA) and therapeutic agent in a ratio of 4:6, so it is very brittle and there is a high risk of implant damage during handling. In order to safely insert the implant into the eye, a transport device that can be driven with controlled force is required. Therefore, in this study, the lever operating force was measured and analyzed to determine the influence of factors according to the cross-sectional thickness and shape of the linkage produced through injection molding as well as the post-process.